Condition: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS · Sponsor: Catherine Bollard
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
This description comes directly from the study's public registry record.
Fahmida Hoq, MBBS, MS · 202-476-3634 · fhoq@childrensnational.org
Always discuss trial participation with your own doctor first.
| Childrens National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Tania Jain, MD | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02203903